ClinicalTrials.gg
RecruitingNCT02426398Updated Oct 2, 2026

Developing a New EEG Method for the Early Diagnosis of Dementia

An observational study in Dementia, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Sheffield Teaching Hospitals NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Started Nov 2014; still recruiting 12 years later.
Updated Oct 2, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
128
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 178 studies in Dementia with a site in United Kingdom — 39 open to participants now, 58 under way, 12 of them phase 3. Dementia · United Kingdom.

Planned enrollment
35th of 54
128 · median 210
Started
2014
with 8 others
Observational
54 of 178
20 open now
Primary completion
2028-06
later than 39 of 57 live
Registered
38th of 178
by date

Among the 178 studies in Dementia with a site in United Kingdom, this one is the 35th largest by planned enrollment of the 54 observational ones that give a count, is one of 9 that started in 2014, is one of 54 observational ones, reaches primary completion later than 39 of the 57 other live ones, and was the 38th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

39 of the 178 studies in Dementia with a site in United Kingdom are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies in Dementia with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a non-invasive study investigating whether EEG, which is used in routine clinical care can be useful in diagnosing dementia. Novel in house developed software will analyse EEG data for this purpose from people with Alzheimer's disease and healthy volunteers.

Read the detailed description

Participant recruitment

15 people with early AD will be recruited from the Sheffield Teaching Hospital and Sheffield Health and Social Care NHS Trusts memory clinics. The STH clinic is neurology led and sees working age (\<65 years old) patients while the SHSC clinic sees an older (>65 years old) population. Over 1300 new assessments are conducted every year. Approximately 65-70% are diagnosed with dementia.

Investigators will choose patients with typical neuropsychological profiles of AD. All patients will have previously been recruited to the Virtual Physiological Human: Dementia Research enabled by IT. VPH-DARE@IT is recruiting 30-40 participants in each of the three following groups (mild AD, MCI and normal controls) and thus our participants will be drawn from this group and all will have pre-existing high-resolution 3D structural and volumetric assessment plus resting-state fMRI scans. This resting-state fMRI data will be analysed to examine the DMN, allowing us to directly compare measures of brain-connectivity between EEG and fMRI and contrast the discriminatory ability of the two methodologies.

10 healthy controls will be aged matched and recruited either from Neurology clinics or be spouses of study participants. The investigators will endeavour to recruit normal controls who have undergone fMRI as part of the academic neuroradiology departments control population for VPH-DARE@IT and other studies.

People with AD and 10 healthy controls will have a repeat EEG to assess the reproducibility and robustness of the EEG measures.

EEG is normally very well tolerated and as listed in the background has been used in many people with dementia. The Clinical Neurophysiology department is very experienced in undertaking EEG in all patient populations from neonates to the very elderly.

Consent Participants will be identified by the clinicians working in the memory clinic or through posters in memory clinic and at other University sites to attract normal volunteers. A Participation Information Sheet (PIS) will be given to them either directly or via post. Participants will have sufficient time to read the PIS and be able to ask questions. The PIS will inform the participant of the benefits and potential risks involved in taking part in this study. They will be made aware of the possibility that incidental changes are rarely detected. If this is seen they would be informed and we would arrange appropriate management. The person will be consented when they come in for the EEG recordings. Investigators will explain to all participants that they will be able to leave the study at any time including during the EEG recording and in those that we plan to repeat the EEG can decline the 2nd test. The Clinical Department of Neurophysiology has experience in performing EEG in all ages including those with dementia and cognitive impairment. The person with dementia's care-giver or family member can come to the department and be in the room for the entire time the EEG recording takes place.

Methodology EEG data capture

  • Participants will attend the department of clinical neurophysiology and a member of the research team will take consent. Two experienced EEG technicians will place the electrodes and explain the procedure. We will record resting state EEG. Participants will be told to lie still with eyes closed. It will be explained that although their eyes are closed they must remain awake. Participants will be continuously monitored and if they become drowsy will be re-stimulated and the time of drowsiness will be recorded. This instruction and monitoring is the same as that used in previous EEG and fMRI studies looking at resting state paradigms.
  • The 10-10 International system of electrode placement will be used for the scalp EEG recordings with a multichannel high sampling rate amplifier (2 KHz). This will provide standard 10/20 electrode positions (F3, F4, F7, F8, C3, C4, Fz, Cz, T3, T4, T5, T6, P3, P4, O1, O2, and Oz electrodes) which will be initially used to detect the more significant spatiotemporal measurements/phenomena while offering the opportunity to elaborate on the spatial and frequency resolution of our findings at a later stage. Peri-ocular EOG electrode data will also be recorded to detect eye movement related slow wave activity. Investigators will therefore be able to avoid spurious estimates of slow wave activity in the anterior EEG regions.
  • Artefact free epochs within suitable (wakeful no task eyes closed state) will be selected and exported for further quantitative EEG analysis.
  • The exported data will be stored on an external encrypted drive.
  • All the analyses will be performed on custom made in-house software on a high tech computer located within secure offices locked within Dr Sarrigannis's office housed in the department of clinical neurophysiology.

EEG Data analyses • The error reduction ratio-causality method will be used to calculate levels of synchronisation. The standard EEG 10-20 electrodes, including all possible contiguous electrode combinations in pairs of two (e.g. right frontocentral versus parietoccipital) will be used in our pilot exploration to assess the 95% confidence interval levels of synchronisation and determine if they allow robust separation between healthy volunteers and patients with Alzheimer's Disease.

Other Data

  • Qualitative Data collection: Investigators will collect questionnaires on the tolerability of undergoing EEG examination (please find enclosed questionnaire).

Ethical consideration Modern neuro-imaging using MRI is highly sensitive and can detect incidental findings. Our novel EEG analyses also have the potential to detect incidental findings. It is well known that spikes during an inter-ictal EEG have limited clinical significance. However they are seen more frequently in people who have a liability, or lowered threshold, for epilepsy. If any concern is raised about the EEG findings the participant will be reviewed by Dr Blackburn and if appropriate referred onto another neurological colleague. Any incidental findings detected by MRI will be referred to an NHS neurologist through the VPH-DARE@IT project researchers. The Patient Information Sheet and consent will make participants aware of these risks before they take part in the study.

Statistics This pilot project will explore EEG data to investigate the frequency and time domain measurement that would be most appropriate for clinical use. Investigators do not know whether this will involve linear or non-linear interaction and thus we cannot determine which is the most appropriate statistical test. The analysis of similar EEG data sets using parametric methods has explored this in more detail.

Power calculations As this is a proof-of-concept, pilot study to examine the robustness of a novel methodology, it is inappropriate to conduct a formal power calculation. Our initial findings will determine whether our EEG analyses detects functional connectivity correlates of the synchronisation of anterior and posterior networks identified by fMRI BOLD signal during resting state scanning. Investigators will also explore if our data is comparable to previously published quantitative EEG on people with AD. Investigators will explore which measures from our data can discriminate people with Alzheimer's disease from healthy controls. These initial results will give us likely effect sizes and allow us to conduct more accurate power calculations than are presently possible. This will be used to determine the sample size of a larger study of people with dementia.

03

Conditions studied

  • Dementia

Browse trials for

Keywords

  • EEG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Clinical diagnosis of possible or probable AD (according to revised diagnostic criteria (McKhann et al., 2011, Dubois et al., 2007)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of possible or probable AD (according to revised diagnostic criteria (McKhann et al., 2011, Dubois et al., 2007)

Exclusion criteria

Exclusion Criteria:

  • Significant vascular change on neuro-imaging (Fazekas grading of white matter change >2) (Fazekas et al., 2002).
  • Clinical history of stroke, Parkinsonism, epilepsy or other neurological disorder. (e.g. severe auditory, visual, language or motor impairment)
  • Moderate to severe dementia (defined by research team but we wouldn't expect those with a [MMSE] ≤ 18 to be able to participate)
  • Severe current mental health disorder (depression, psychosis).
  • Patients on sedating or antiepileptic medication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
128 participants (estimated)
Patient registry
No

Groups and cohorts

  • People with Alzheimer's disease

    People with Alzheimer's disease

  • Healthy volunteers

    Healthy volunteers

06

What researchers measure

Primary outcomes

  1. Significant spatiotemporal measurements from EEG

    EEG data analysis

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2014 (actual). Primary completion is estimated for Jun 2028, 162 months after the start.

Of 272 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's planned 162 months is above that.

Counting every sponsor, half of 294 studies reached it within 65 months; a quarter within 29 and three quarters within 188.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Mar 2015 → Nov 2014, primary completion Dec 2024 → Jun 2028 and completion Dec 2024 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2015
First posted
Apr 24, 2015
StartActual
Nov 19, 2014was Mar 2015
Primary completionEst.
Jun 1, 2028was Dec 2024
CompletionEst.
Jun 1, 2028was Dec 2024
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 2015→Nov 19, 2014 (actual)
Oct 2, 2026
Primary completion
Dec 31, 2024→Jun 1, 2028
Oct 2, 2026
Study completion
Dec 31, 2024→Jun 1, 2028
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Start date Mar 2015→Nov 19, 2014 (now actual)
    Primary completion Dec 31, 2024→Jun 1, 2028
    Study completion Dec 31, 2024→Jun 1, 2028
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02426398
Responsible party
Sponsor
First posted
Apr 24, 2015
Start date
Nov 19, 2014
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Daniel Blackburn, MBChB, PhD
Contact
d.blackburn@shef.ac.uk
01142222267
Jodie Keyworth
Contact
j.keyworth@shef.ac.uk
Daniel Blackburn, MBChB, PhD
principal investigator · Sheffield Teaching Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion